Skip to main content
Clinical Trials/NCT02688413
NCT02688413
Terminated
Not Applicable

Randomized Parallel-group Study Evaluating the Effectiveness and Cost-effectiveness of the Co-administration of MindMotionPRO Plus Standard Practice Versus Standard Practice in Early Post-stroke Upper-limb Rehabilitation

Mindmaze SA3 sites in 3 countries9 target enrollmentAugust 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Mindmaze SA
Enrollment
9
Locations
3
Primary Endpoint
Rehabilitation dose as measured by the duration of the rehabilitation session without planned rest periods
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

Randomised controlled multi-centered study using MindMotionPRO, an immersive virtual reality based system for upper limb motor rehabilitation in early post-stroke patients. The study aims to evaluate the ability of MindMotionPRO technology to increase the rehabilitation dose. Effectiveness will be evaluated by validated rehabilitation performance scales. Cost-effectiveness will be assessed by the resource utilization.

Detailed Description

The goal of the study is to show that MindMotionPRO is a tool that allows a patient to increase the amount of rehabilitation therapy performed. This study will measure the rehabilitation dose, as measured by the duration of the rehabilitation session and the number of exercises performed by the patient. The study hypothesis is that patients in the MindMotionPRO group will spend more time performing rehabilitation exercises than in the Self-Directed Prescribed exercises group. The effectiveness of the MindMotionPRO versus Self-Directed Prescribed Exercises will also be measured, based on the change in rehabilitation performance measures. The cost-effectiveness will be measured by the resource utilization, as defined by the time spent by the therapist providing the rehabilitation session.

Registry
clinicaltrials.gov
Start Date
August 2016
End Date
February 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male/female \> 18 years old
  • First ever unilateral supratentorial ischemic stroke with contralateral upper extremity weakness
  • 1 to 6 weeks post-stroke
  • Able to give informed consent
  • Not participating any other intervention studies
  • Experiencing motor difficulties in using the paretic arm, with a FMA-UE score in the range of 20 to 40 out of 66
  • Stroke severity with NIHSS score between 5 (mild) and 14 (moderate) out of 42
  • The participant is expected to remain available (geographically stable) for 4 months after enrolment.

Exclusion Criteria

  • Any medical condition compromising the safety or the ability to take part to the study (such as insufficient vision or hearing, inability to participate to therapy session, inability to communicate, upper limb condition not linked to stroke, uncontrolled blood pressure, uncontrolled diabetes, co-morbidity)
  • Recurrent and moderate to high upper limb pain limiting delivery of rehabilitation dose
  • History of more than one epileptic seizures since stroke onset or uncontrolled epileptic seizure
  • Mild to severe cognitive impairment (Mini mental state exam (MMSE) score \< 24/30)
  • Depression (Hospital Anxiety and Depression Scale \> 8/21)
  • Moderate to severe hemispatial neglect compromising the ability to take part to the study, as determined by the Bells tests (\> 6 errors)
  • Brain stem stroke

Outcomes

Primary Outcomes

Rehabilitation dose as measured by the duration of the rehabilitation session without planned rest periods

Time Frame: 4 weeks

Secondary Outcomes

  • Change from Baseline in upper extremity motor ability measured by the streamlined Wolf Motor Function Test (sWMFT) score(baseline, 4 weeks, 16 weeks)
  • Change from Baseline in the severity of stroke symptoms as measured by the NIH stroke scale (NIHSS)(baseline, 4 weeks, 16 weeks)
  • Motivation measured by the Intrinsic Motivation Index (IMI)(1 week and 4 weeks)
  • Number of exercises performed(4 weeks)
  • Change from Baseline in self-care ability measured by the Barthel index (BI)(baseline, 4 weeks, 16 weeks)
  • Change from Baseline in arm function in daily activities as measured by the Motor Activity Log (MAL)(baseline, 4 weeks, 16 weeks)
  • Change from Baseline in functional independence measured by the Modified Ranking Scale (MRS) and associated disability-adjusted life year (DALY)(baseline, 4 weeks, 16 weeks)
  • Change from Baseline in the general health status as measured by the Stroke Impact scale (SIS)(baseline, 4 weeks, 16 weeks)
  • Change from Baseline in upper extremity motor function measured by the Fugl-Meyer Assessment for Upper Extremity (FMA-UE) and its subscales(baseline, 4 weeks, 16 weeks)

Study Sites (3)

Loading locations...

Similar Trials